MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Forest Laboratories (NYSE: FRX)
Finance & Acquisitions:Forest Labs
Aptalis Pharmaceutical Technologies
Parents
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Companies: Acquired_(M&A)
Finance & Acquisitions:Forest Labs
Children
Aptalis had sales of $688 million in FY2013
Bridgewater Based Aptalis Pharmaceutical Files To Raise $500 Million In IPO (2013)
Forest Laboratories Inc Scoops Up Aptalis for $2.9 billion (2014)
Frank Verwiel MD, Chief Executive Officer of Aptalis (2014)
Specialty Gastrointestinal (GI) and Cystic Fibrosis company